- Home
- XBIT vs AVIR Comparison
XBIT vs AVIR Comparison
Compare XBIT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- AVIR
- Stock Information
- Founded
- XBIT 2005
- AVIR 2012
- Country
- XBIT United States
- AVIR United States
- Employees
- XBIT N/A
- AVIR N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- XBIT Health Care
- AVIR Health Care
- Exchange
- XBIT Nasdaq
- AVIR Nasdaq
- Market Cap
- XBIT 211.9M
- AVIR 247.5M
- IPO Year
- XBIT 2015
- AVIR 2020
- Fundamental
- Price
- XBIT $6.27
- AVIR $3.29
- Analyst Decision
- XBIT
- AVIR Hold
- Analyst Count
- XBIT 0
- AVIR 1
- Target Price
- XBIT N/A
- AVIR $6.88
- AVG Volume (30 Days)
- XBIT 72.1K
- AVIR 491.5K
- Earning Date
- XBIT 11-13-2024
- AVIR 11-07-2024
- Dividend Yield
- XBIT N/A
- AVIR N/A
- EPS Growth
- XBIT N/A
- AVIR N/A
- EPS
- XBIT N/A
- AVIR N/A
- Revenue
- XBIT N/A
- AVIR N/A
- Revenue This Year
- XBIT N/A
- AVIR N/A
- Revenue Next Year
- XBIT N/A
- AVIR N/A
- P/E Ratio
- XBIT N/A
- AVIR N/A
- Revenue Growth
- XBIT N/A
- AVIR N/A
- 52 Week Low
- XBIT $3.83
- AVIR $2.75
- 52 Week High
- XBIT $9.96
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- XBIT 42.25
- AVIR 49.07
- Support Level
- XBIT $6.06
- AVIR $3.10
- Resistance Level
- XBIT $7.24
- AVIR $3.27
- Average True Range (ATR)
- XBIT 0.51
- AVIR 0.16
- MACD
- XBIT -0.03
- AVIR 0.02
- Stochastic Oscillator
- XBIT 17.72
- AVIR 55.28
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).